OrbiMed’s TG Therapeutics TGTX Stock Holding History

OrbiMed’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$3.61M	–	128
2025 Q3	$3.61M	Buy	+100,000	New	+$3.29M	0.08%	95
2023 Q3	–	Sell	-45,800	Closed	-$1.14M	–	138
2023 Q2	$1.14M	Buy	+45,800	New	+$1.18M	0.02%	120

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

OrbiMed's TGTX Position: Q3 2024 in Review

OrbiMed sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 133,200 shares — an estimated $2.37M sold.

OrbiMed first reported a position in TGTX in Q2 2024 and held it in 1 quarter. The position peaked at $2.37M in Q2 2024. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

OrbiMed reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
OrbiMed sold 133,200 TG Therapeutics shares in Q3 2024, an estimated $2.37M.
OrbiMed first reported a position in TG Therapeutics in Q2 2024 and held it in 1 quarter.
OrbiMed's TG Therapeutics position peaked at $2.37M in Q2 2024.
308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.